Physician profile
Sherry Kuo
NPI 1184839011
$30,163.39
in general payments reported to CMS, 2019-2025
18 companies · $399 in 2025
The $399 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $1,448 · 2021: $189 · 2022: $3,804 · 2023: $14K · 2024: $483 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $1,387 · Travel and Lodging: $250 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,900.00 |
| Food and Beverage | $1,386.87 |
| Travel and Lodging | $250.21 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $27,466.61 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $548.94 | 2020-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.36 | 2019-2023 | Ofev |
| Actelion Pharmaceuticals US, INC. | $368.25 | 2019-2025 | Opsumit, Uptravi |
| Grifols USA, LLC | $273.46 | 2019-2022 | |
| Genzyme Corporation | $238.80 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $224.40 | 2019-2025 | Dupixent |
| Insmed, INC. | $139.93 | 2019 | |
| Amgen INC. | $118.34 | 2023 | Tezspire |
| United Therapeutics Corporation | $102.65 | 2019-2025 | Tyvaso |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Genentech, INC. | $58.76 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.16 | 2019-2020 | |
| Verona Pharma, INC. | $29.40 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $27.41 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $20.81 | 2024 | Xolair |
| Breas Medical, INC. | $16.79 | 2024 | Vivo 45 Ls |
| Merck Sharp & Dohme LLC | $16.33 | 2025 | Winrevair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Kuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.